Pulmonary surfactant: functions, abnormalities and therapeutic options.
about
A Pathophysiologic Approach to Biomarkers in Acute Respiratory Distress SyndromeAlveolar type II epithelial cell dysfunction in rat experimental hepatopulmonary syndrome (HPS)Disaturated-phosphatidylcholine and surfactant protein-B turnover in human acute lung injury and in control patientsTransient in utero disruption of cystic fibrosis transmembrane conductance regulator causes phenotypic changes in alveolar type II cells in adult rats.The effect of matrix metalloproteinase-3 deficiency on pulmonary surfactant in a mouse model of acute lung injury.Molecular dynamics simulations of a pulmonary surfactant protein B peptide in a lipid monolayer.Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis.In vivo detection of acinar microstructural changes in early emphysema with (3)He lung morphometrySurfactant disaturated-phosphatidylcholine kinetics in acute respiratory distress syndrome by stable isotopes and a two compartment model.Interdependent TTF1 - ErbB4 interactions are critical for surfactant protein-B homeostasis in primary mouse lung alveolar type II cellsCurrent concepts on the pulmonary surfactant in infants.A ubiquitous membrane fusion protein alpha SNAP: a potential therapeutic target for cancer, diabetes and neurological disorders?Atomic force microscopy studies of functional and dysfunctional pulmonary surfactant films, II: albumin-inhibited pulmonary surfactant films and the effect of SP-APulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease.Pharmacotherapy of acute lung injury and acute respiratory distress syndromeDelivery and performance of surfactant replacement therapies to treat pulmonary disorders.The role of toll-like receptors in acute and chronic lung inflammation.Exogenous pulmonary surfactant for acute respiratory distress syndrome in adults: A systematic review and meta-analysis.Calf Lung Surfactant Recovers Surface Functionality After Exposure to Aerosols Containing Polymeric Particles.κB-Ras proteins regulate both NF-κB-dependent inflammation and Ral-dependent proliferation.The influence of natural pulmonary surfactant on the efficacy of siRNA-loaded dextran nanogels.Allergen particle binding by human primary bronchial epithelial cells is modulated by surfactant protein DEffect of pulmonary surfactant protein SP-B on the micro- and nanostructure of phospholipid films.Hypoxia-induced mitogenic factor modulates surfactant protein B and C expression in mouse lungThe effect of diet-induced serum hypercholesterolemia on the surfactant system and the development of lung injury.The effect of a C-terminal peptide of surfactant protein B (SP-B) on oriented lipid bilayers, characterized by solid-state 2H- and 31P-NMR.KL4-surfactant (Lucinactant) protects human airway epithelium from hyperoxia.Effect of acute lung injury on structure and function of pulmonary surfactant films.Surfactant protein-A and phosphatidylglycerol suppress type IIA phospholipase A2 synthesis via nuclear factor-kappaB.Protein inhibition of surfactant during mechanical ventilation of isolated rat lungs.Intrauterine tobacco smoke exposure and hyaline membrane disease amongst triplets.Pulmonary surfactant, lung function, and endobronchial inflammation in cystic fibrosis.High oxygen concentrations predispose mouse lungs to the deleterious effects of high stretch ventilation.Early surfactant administration protects against lung dysfunction in a mouse model of ARDS.Structure and dynamics of interfacial water in model lung surfactants.Deleterious role of TLR3 during hyperoxia-induced acute lung injury.Competence-induced protein Ccs4 facilitates pneumococcal invasion into brain tissue and virulence in meningitis
P2860
Q26765351-C697DC8C-0CEC-4FFC-8BE7-27D6A0E75927Q27323988-186214B9-6068-4FDE-8821-36B4BDA2D8F6Q28307833-63FB72E6-C46C-49AA-8D5B-FE5B4110A33DQ33424993-B487B8BF-507F-44CC-A5A3-F7842E2FB3CAQ33924226-62D543BC-23B9-4B88-9F66-37FD37BF2E37Q34180760-2A963D65-7020-487B-824D-9D1932806D36Q34999391-4E99D0E2-766F-4386-ACF4-E9EA1EBD65FEQ35167397-A8ABF08B-90CF-4485-8A01-F65D2A58CFAAQ35674841-6E985228-3F66-47F7-BB61-19CF82E05EBBQ36087421-02636400-FC7F-4CEA-8CC3-41CB88C9124CQ36359561-E128FEBE-3F61-4D15-B4A9-C4FB2C671A3AQ36596690-9435C675-87F7-415F-BC0C-F43EAA912692Q36856485-DAB58CB3-9F4A-4719-A9CB-65131ADADAE9Q37082562-73F8AA3D-FA82-4EDB-A0B4-CB015B37874AQ37085611-EECCDDD3-5C97-4E9D-B210-B096BE0F2522Q37341712-C5A0CFAA-8C1F-4055-AF19-28CB26CBBC86Q37812405-86264457-CAF5-4CAB-A527-846184BFA65EQ38068408-28E07D38-14C1-412B-9A1A-3266592D2AD5Q38674690-2518880C-8201-46CA-A97A-F898E78C0E65Q38956617-AA3CDB9B-2344-4B2C-8910-89C5B96DC67DQ39192476-88234B3F-B391-4D72-8811-6B5E70E23EC1Q39689683-F981043D-D5E0-4901-BF52-C5C3C21596DBQ40268018-24445724-B867-4A44-826B-1EC7CFE9B984Q40372585-3B2C2801-5D8A-4867-9FE2-4BF54AD96714Q41129561-D7088BBB-B174-46AA-932A-6F520A406B48Q41836928-6346DD21-7B3E-4CFC-B80A-D7A5F67324FBQ44313418-4F09B2E2-0936-47AD-BAFA-DA4B8691A21DQ44663894-BB417D8E-4FB7-4C47-B94C-6BC4CABA9FD6Q46504389-57EE9727-F6CE-4041-B914-492B1E7CB275Q47716759-C4B808BD-DD61-464D-9EB9-4D926B975F04Q47732519-DFB68DC3-30D2-4ACA-836A-979CB5228366Q47952113-0CB3E6CC-4715-4D7C-8878-ECEA036DB450Q51687704-B680FF36-FEBC-49D4-8B38-6FD0CC0665E7Q51690181-8B2EC1DA-A8E4-49BE-89BA-0E9329F74904Q51813138-539E4529-101A-4085-93DB-B3711803A4A4Q52589672-4610E4F4-7E9C-4ACD-99AC-EC80CFEB1BE6Q58697374-8D24BE8A-618A-4F1F-BF50-03642BCD8EBC
P2860
Pulmonary surfactant: functions, abnormalities and therapeutic options.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pulmonary surfactant: functions, abnormalities and therapeutic options.
@ast
Pulmonary surfactant: functions, abnormalities and therapeutic options.
@en
Pulmonary surfactant: functions, abnormalities and therapeutic options.
@nl
type
label
Pulmonary surfactant: functions, abnormalities and therapeutic options.
@ast
Pulmonary surfactant: functions, abnormalities and therapeutic options.
@en
Pulmonary surfactant: functions, abnormalities and therapeutic options.
@nl
prefLabel
Pulmonary surfactant: functions, abnormalities and therapeutic options.
@ast
Pulmonary surfactant: functions, abnormalities and therapeutic options.
@en
Pulmonary surfactant: functions, abnormalities and therapeutic options.
@nl
P2093
P1476
Pulmonary surfactant: functions, abnormalities and therapeutic options.
@en
P2093
P2888
P304
P356
10.1007/S00134-001-1121-5
P577
2001-10-30T00:00:00Z